BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

49 related articles for article (PubMed ID: 38506024)

  • 21. Diagnosis, Management, and New Therapeutic Options in Childhood Neurofibromatosis Type 2 and Related Forms.
    Ruggieri M; Praticò AD; Evans DG
    Semin Pediatr Neurol; 2015 Dec; 22(4):240-58. PubMed ID: 26706012
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bilateral Vestibular Schwannomas in a Patient with Ring Chromosome 22: Case Report and Review of the Literature.
    Nussbaum PE; Patel PD; Nussbaum LA; Hilton CW; Nussbaum ES
    Pediatr Neurosurg; 2021; 56(1):56-60. PubMed ID: 33550291
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Neurofibromatosis type 2.
    Evans DG
    Handb Clin Neurol; 2015; 132():87-96. PubMed ID: 26564072
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Preservation of auditory and vestibular function after surgical removal of bilateral vestibular schwannomas in a patient with neurofibromatosis type 2.
    Black FO; Brackmann DE; Hitselberger WE; Purdy J
    Am J Otol; 1995 Jul; 16(4):431-43. PubMed ID: 8588642
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Targeted Therapies in the Treatment of Vestibular Schwannomas: Current State and New Horizons.
    Welling DB
    Otolaryngol Clin North Am; 2023 Jun; 56(3):543-556. PubMed ID: 37024334
    [TBL] [Abstract][Full Text] [Related]  

  • 26. An update on the CNS manifestations of neurofibromatosis type 2.
    Coy S; Rashid R; Stemmer-Rachamimov A; Santagata S
    Acta Neuropathol; 2020 Apr; 139(4):643-665. PubMed ID: 31161239
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Neurofibromatosis type 2 (NF2): a clinical and molecular review.
    Evans DG
    Orphanet J Rare Dis; 2009 Jun; 4():16. PubMed ID: 19545378
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Neurofibromatosis type 2.
    Slattery WH
    Otolaryngol Clin North Am; 2015 Jun; 48(3):443-60. PubMed ID: 26043141
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Systematic Review of Radiosurgery Versus Surgery for Neurofibromatosis Type 2 Vestibular Schwannomas.
    Chung LK; Nguyen TP; Sheppard JP; Lagman C; Tenn S; Lee P; Kaprealian T; Chin R; Gopen Q; Yang I
    World Neurosurg; 2018 Jan; 109():47-58. PubMed ID: 28882713
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Microdeletion del(22)(q12.2) encompassing the facial development-associated gene, MN1 (meningioma 1) in a child with Pierre-Robin sequence (including cleft palate) and neurofibromatosis 2 (NF2): a case report and review of the literature.
    Davidson TB; Sanchez-Lara PA; Randolph LM; Krieger MD; Wu SQ; Panigrahy A; Shimada H; Erdreich-Epstein A
    BMC Med Genet; 2012 Mar; 13():19. PubMed ID: 22436304
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ipsilateral Cochlear Implantation in the Presence of Observed and Irradiated Vestibular Schwannomas.
    Urban MJ; Moore DM; Kwarta K; Leonetti J; Rajasekhar R; Gluth MB; Wiet RM
    Ann Otol Rhinol Laryngol; 2020 Dec; 129(12):1229-1238. PubMed ID: 32551844
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Advances in Targeted Therapy for Neurofibromatosis Type 2 (NF2)-Associated Vestibular Schwannomas.
    Cumpston EC; Rhodes SD; Yates CW
    Curr Oncol Rep; 2023 May; 25(5):531-537. PubMed ID: 36933171
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Neurofibromatosis.
    Roos KL; Muckway M
    Dermatol Clin; 1995 Jan; 13(1):105-11. PubMed ID: 7712636
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Neurofibromatosis Type 2 (NF2) and the Implications for Vestibular Schwannoma and Meningioma Pathogenesis.
    Bachir S; Shah S; Shapiro S; Koehler A; Mahammedi A; Samy RN; Zuccarello M; Schorry E; Sengupta S
    Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33445724
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Genomics, Epigenetics, and Hearing Loss in Neurofibromatosis Type 2.
    Dinh CT; Nisenbaum E; Chyou D; Misztal C; Yan D; Mittal R; Young J; Tekin M; Telischi F; Fernandez-Valle C; Liu XZ
    Otol Neurotol; 2020 Jun; 41(5):e529-e537. PubMed ID: 32150022
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The neurofibromatoses. Part 2: NF2 and schwannomatosis.
    Lu-Emerson C; Plotkin SR
    Rev Neurol Dis; 2009; 6(3):E81-6. PubMed ID: 19898272
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Diagnostic and Prognostic Relevance of the Cutaneous Manifestations of Neurofibromatosis Type 2.
    Plana-Pla A; Bielsa-Marsol I; Carrato-Moñino C;
    Actas Dermosifiliogr; 2017 Sep; 108(7):630-636. PubMed ID: 28237041
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Neurofibromatosis type 2.
    Uppal S; Coatesworth AP
    Int J Clin Pract; 2003 Oct; 57(8):698-703. PubMed ID: 14627181
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hearing optimisation in neurofibromatosis type 2: A systematic review.
    Lloyd SKW; King AT; Rutherford SA; Hammerbeck-Ward CL; Freeman SRM; Mawman DJ; O'Driscoll M; Evans DG
    Clin Otolaryngol; 2017 Dec; 42(6):1329-1337. PubMed ID: 28371358
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.